BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This collaboration marks an important step forward for BioCryst in expanding the global market presence of its core products.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyzing Bittensor’s 7% drop after its Raydium rally – What’s next for TAO?
AMBCrypto•2026/09/12 02:03
Hyperscale Data Executive Chairman Milton C. Ault III buys USD 5,252 of common shares
Reuters•2026/09/12 01:59
Will Gold Price Fall Below $4,000 Amid Renewed Economic Risks?
BeInCrypto•2026/09/12 01:57
IonQ director and special advisor Raymond John w sells USD 89,578.47 in common shares
Reuters•2026/09/12 01:55
